Novel Isolongifolenone-Based Caprolactam Derivatives as Potential Anticancer Agents via the p53/mTOR/Autophagy Pathway
Molecules · 2025
DOI: 10.3390/molecules30194013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Yunyun Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, China. Hauptthemen laut MEDLINE: Autophagy, TOR Serine-Threonine Kinases, Antineoplastic Agents, Tumor Suppressor Protein p53. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Province Science and Technology Department, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Isolongifolenone, a natural sesquiterpenoid widely used in food additives and perfume, demonstrates a range of biological activities. In this study, a series of isolongifolenone-based caprolactam derivatives (E1–E19) were designed, synthesized, and evaluated for their anticancer activities in vitro. Most of the synthesized compounds significantly inhibited the proliferation of cultured cancer cells. Compound E10, containing an m-trifluoromethyl group, demonstrated the strongest anti-proliferation activities against MCF-7 (IC50 = 0.32 µM), HepG2 (IC50 = 1.36 µM), and A549 (IC50 = 1.39 µM) cells. Moreover, E10 was shown to increase intracellular ROS, reduce mitochondrial function, and induce cancer cell apoptosis via the p53/mTOR/autophagy pathway. Together, these results indicate that compound E10 induced autophagy-associated cell apoptosis in MCF-7 cancer cells. Additionally, the antitumor activity of E10 was validated in a zebrafish MCF-7 xenograft model. The observation that E10 exhibits potent antitumor activity in both a three-dimensional (3D) cell culture model and the zebrafish xenograft model supports the development of E10 as a potential drug candidate for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, China.
- Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing 210037, China.
- Engineering Research Center of Zebrafish Models for Human Diseases and Drug Screening of Shandong Province, Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.
ORCID-Profile: Yunyun Wang, Peihai Li
Förderung
- Jiangsu Province Science and Technology Department
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Wang, Y., Hu, M., Han, J., Zhao, Y., Xiong, B., Li, P., & Wang, S. (2025). Novel Isolongifolenone-Based Caprolactam Derivatives as Potential Anticancer Agents via the p53/mTOR/Autophagy Pathway. Molecules. https://doi.org/10.3390/molecules30194013
Vancouver
Wang Y, Hu M, Han J, Zhao Y, Xiong B, Li P, et al. Novel Isolongifolenone-Based Caprolactam Derivatives as Potential Anticancer Agents via the p53/mTOR/Autophagy Pathway. Molecules. 2025. doi:10.3390/molecules30194013
BibTeX
@article{Wang2025,
author = {Wang, Yunyun and Hu, Min and Han, Jiale and Zhao, Yuxun and Xiong, Biao and Li, Peihai and Wang, Shifa},
title = {Novel Isolongifolenone-Based Caprolactam Derivatives as Potential Anticancer Agents via the p53/mTOR/Autophagy Pathway},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30194013}
}
EUVIMED